ATE452982T1 - Verfahren zur verabreichng von nukleinsäuren in zellen in vitro oder ex vivo - Google Patents

Verfahren zur verabreichng von nukleinsäuren in zellen in vitro oder ex vivo

Info

Publication number
ATE452982T1
ATE452982T1 AT99401687T AT99401687T ATE452982T1 AT E452982 T1 ATE452982 T1 AT E452982T1 AT 99401687 T AT99401687 T AT 99401687T AT 99401687 T AT99401687 T AT 99401687T AT E452982 T1 ATE452982 T1 AT E452982T1
Authority
AT
Austria
Prior art keywords
cells
vitro
vivo
administration
nucleic acids
Prior art date
Application number
AT99401687T
Other languages
English (en)
Inventor
Francois Lemoine
David Klatzmann
Mojgan Movassagh
Jean-Loup Salzmann
Original Assignee
Univ Paris Curie
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Paris Curie filed Critical Univ Paris Curie
Application granted granted Critical
Publication of ATE452982T1 publication Critical patent/ATE452982T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/13043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/13045—Special targeting system for viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13051—Methods of production or purification of viral material
    • C12N2740/13052—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/60—Vectors comprising as targeting moiety peptide derived from defined protein from viruses
    • C12N2810/6045—RNA rev transcr viruses
    • C12N2810/6054—Retroviridae
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT99401687T 1998-07-10 1999-07-06 Verfahren zur verabreichng von nukleinsäuren in zellen in vitro oder ex vivo ATE452982T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11328098A 1998-07-10 1998-07-10

Publications (1)

Publication Number Publication Date
ATE452982T1 true ATE452982T1 (de) 2010-01-15

Family

ID=22348556

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99401687T ATE452982T1 (de) 1998-07-10 1999-07-06 Verfahren zur verabreichng von nukleinsäuren in zellen in vitro oder ex vivo

Country Status (4)

Country Link
EP (1) EP0995802B1 (de)
JP (1) JP2000139478A (de)
AT (1) ATE452982T1 (de)
DE (1) DE69941836D1 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9493789B2 (en) * 2014-04-24 2016-11-15 Miltenyi Biotec Gmbh Automated generation of genetically modified stem cells
WO2016073602A2 (en) * 2014-11-05 2016-05-12 Juno Therapeutics, Inc. Methods for transduction and cell processing
EP3858365B1 (de) * 2016-09-01 2024-01-31 Chimera Bioengineering Inc. Goldoptimierte car-t-zellen

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5017492A (en) * 1986-02-27 1991-05-21 Life Technologies, Inc. Reverse transcriptase and method for its production
EP0857217B1 (de) * 1995-10-16 2005-04-13 Dana-Farber Cancer Institute Neue expressionsvektoren und verfahren zu deren verwendung
DE69739286D1 (de) * 1996-05-06 2009-04-16 Oxford Biomedica Ltd Rekombinationsunfähige retrovirale vektoren
EP1161549A2 (de) * 1999-03-15 2001-12-12 Chiron Corporation Retroviren hellstellende zellen, die viele transduktionen verwenden

Also Published As

Publication number Publication date
EP0995802A2 (de) 2000-04-26
DE69941836D1 (de) 2010-02-04
JP2000139478A (ja) 2000-05-23
EP0995802A3 (de) 2001-01-10
EP0995802B1 (de) 2009-12-23

Similar Documents

Publication Publication Date Title
Baramova et al. Degradation of extracellular matrix proteins by hemorrhagic metalloproteinases
Higuchi et al. DNA sequences from the quagga, an extinct member of the horse family
ATE318896T1 (de) Rekombinante rna-replikase von hepatitis-c-virus
DE59912118D1 (de) Verfahren zur herstellung von genetisch modifizierten cd34-negativen, adhärent wachsenden hämatopoietischen stammzellen
ATE237312T1 (de) In liposomen verkapselte nukleinsäurekomplexe
ATE85361T1 (de) Molekulare zuechtung.
ES8800343A1 (es) Un metodo para producir una proteina que contiene actividad biologica para coagulacion de sangre, mediada por factor viia
ATE87663T1 (de) Verfahren zur herstellung von faktor-viii:c-typ- proteinen.
ATE195148T1 (de) Prozess zur rekombinanten herstellung von hiv-2 - proteinen sowie zellen, die hiv-2 - proteine exprimiert
ATE278024T1 (de) Methode zur herstellung von rekombinanten zellen
DE69720026D1 (de) Verfahren zur herstellung von d-aminosäuren durch direkte gärung
ATE391175T1 (de) Multidrug resistenz gen
DE69131069D1 (de) Plasmid das für die aminosäuresequenz von tcf-ii kodierende dns enthalt, transformierte zelle und produktion einer physiologisch aktiven substanz mit ihrer verwendung
ATE339511T1 (de) Natürliche oder synthetische retroelement- sequenzen, die die insertion von nukleotiden in eukaryotische zellen erlauben
ES8301503A1 (es) Procedimiento para la produccion de un microorganismo gene- ticamente modificado
KR880009991A (ko) 항혈액응고작용을 갖는 폴리펩티드
ATE452982T1 (de) Verfahren zur verabreichng von nukleinsäuren in zellen in vitro oder ex vivo
DE60038630D1 (de) Verfahren zur ex vivo bildung von säugetier-knochen und dessen verwendungen
DE68929296D1 (de) Verfahren zur biochemischen Oxidation von Steroiden sowie dafür verwendbare, genetisch manipulierte Zellen
DE69529750D1 (de) Verbesserungen in der herstellung von proteinen in wirtszellen
ES2065915T3 (es) Procedimiento para aumentar la expresion de polipeptidos en un cultivo de celula recombinante.
DE69425809D1 (de) Methoden zur Herstellung von Protein C
ES2061524T3 (es) Un vector plasmidico para la expresion en bacillus y empleado para la clonacion del gen estructural que codifica la hormona de crecimiento humana y un metodo para la produccion de la hormona.
ES2053766T3 (es) Metodo para aumentar la expresion de un gen.
DE60030621D1 (de) DNA-Konstrukt zur gewebespezifischen Expression eines Blutkgerinnungsfaktors

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties